We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ready-Made Cardiac Patch Repairs Heart Attack Damage

By HospiMedica International staff writers
Posted on 23 Apr 2020
A new study describes how a freezable, cell-free, artificial cardiac patch can deliver healing factors directly to the site of myocardial injury. More...


Developed at the University of North Carolina (UNC; Chapel Hill, USA) and North Carolina State University (NC State; Raleigh, USA), the new off-the-shelf fully acellular artificial cardiac patch (artCP) is composed of a porcine-based decellularized myocardial extracellular matrix (ECM) scaffold and synthetic encapsulated secreted factors retrieved from isolated human cardiac stromal cells. The artCP thus contains all of the therapeutics secreted by the cells, but without live cells that could trigger an immune response.

In a rat model of acute myocardial infarction (MI), subsequent transplantation of the artCP supported cardiac recovery over a three-week period by promoting angiomyogenesis, reducing scarring by 30%, and improving cardiac function by 50%. The safety and efficacy of the artCP were further confirmed in a porcine model of MI. And while cellular-based scaffold patches need to be freshly prepared to maintain cell viability, the artCP can maintain its potency even after long-term cryopreservation. The study was published on April 8, 2020, in Science Translational Medicine.

“We have developed an artificial cardiac patch that can potentially solve the problems associated with using live cells, yet still deliver effective cell therapy to the site of injury. The patch can be frozen and safely stored for at least 30 days,” said senior author Professor Ke Cheng, PhD, of the NC State/UNC Joint Department of Biomedical Engineering. “Since there are no live cells involved, it will not trigger a patient’s immune system to reject it. It is a first step toward a truly off-the-shelf solution to cardiac patch therapy.”

Cell therapy for cardiac remodeling after MI is therapeutic, in part, because of the paracrine effects of factors secreted from human cardiac stromal cells. But low retention and engraftment of transplanted cells can limit potential therapeutic efficacy, while seeding of a scaffold material with cells to create cardiac patches that can be transplanted onto the surface of the heart is a costly, time-consuming procedure, and since they use live cellular material, can increase the risk of tumor formation and arrhythmia.

Related Links:
University of North Carolina
North Carolina State University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.